ACM
GPCR icon

ADAR1 Capital Management’s Structure Therapeutics GPCR Stock Holding History

ADAR1 Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-800
Closed -$34.3K – 290
2024
Q1 		$34.3K Buy
+800
New +$33.7K 0.01% 201

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ADAR1 Capital Management's GPCR Position: Q2 2026 in Review

ADAR1 Capital Management opened a new position in Structure Therapeutics (GPCR) in Q2 2026: 17,500 shares worth $939K. The stake represents 0.04% of the portfolio and ranks #174 among its holdings. This is a return to the name: ADAR1 Capital Management previously reported a position in GPCR as recently as Q3 2025.

ADAR1 Capital Management first reported a position in GPCR in Q4 2023 and has held it in 8 quarters since. The position peaked at $958K in Q4 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • ADAR1 Capital Management held 17,500 shares of Structure Therapeutics worth $939K as of Q2 2026.
  • Structure Therapeutics was a new ADAR1 Capital Management position in Q2 2026.
  • Structure Therapeutics made up 0.04% of ADAR1 Capital Management's portfolio in Q2 2026, its #174 holding.
  • ADAR1 Capital Management first reported a position in Structure Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • ADAR1 Capital Management's Structure Therapeutics position peaked at $958K in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.